Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

NCT07816666 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07816666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07816666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 29, 2026
Completion date
October 27, 2031
Enrollment
600 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-sensitive relapsed epithelial ovarian cancer, platinum-sensitive relapsed fallopian tube cancer, platinum-sensitive relapsed primary peritoneal cancer